—
C+
C+ The full Closelook — membership. Open the C+ overview

Neurocrine Biosciences Inc (NBIX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Neurocrine Biosciences Inc

NBIX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Neurocrine Biosciences develops and sells medicines for neurological, psychiatric and endocrine conditions, working mainly across the United States. Its main marketed drug, INGREZZA, treats tardive dyskinesia and chorea linked to Huntington's disease, alongside Orilissa and Oriahnn for gynaecological conditions and CRENESSITY for a rare adrenal disorder. It also markets ALKINDI and Efmody and runs a pipeline of experimental compounds aimed at depression, schizophrenia, epilepsy, Alzheimer's disease and obesity, several developed under partnerships with firms such as Takeda, AbbVie, Sanofi, Xenon and Voyager. The company is based in San Diego, California.
Where it sits in the stack
Neurocrine is not part of our AI build-out stack; it sits in the healthcare sleeve of our universe, within specialty drug manufacturing, as a developer and seller of neurological and endocrine therapies rather than a supplier to the compute or chip industries.
Who it is priced against
Closelook has not placed Neurocrine in a formal peer group; the market tends to set it beside other specialty neuroscience and psychiatric drug makers, such as Jazz Pharmaceuticals.
Why Closelook tracks it
Neurocrine holds a Russell 1000 seat within our coverage but carries no Closelook score yet, no Rubin or Halo membership, and no quotes or edition mentions in the diary so far.
What the diary watches
The diary watches whether pipeline readouts across depression, schizophrenia and epilepsy candidates progress toward approval, given how much of current revenue still rests on INGREZZA.

Neurocrine Biosciences Inc (NBIX) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for NBIX, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Morgan Stanley, 2026-09-11

The Street on this name

Analyst actions and the latest print for NBIX from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Morgan Stanley — target 183 from 182 Target raised to $183 from $182 (+16.9% to spot) 2026-09-11

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - Specialty & Generic · United States · 5 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against NBIX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Neurocrine Biosciences Inc (NBIX)?

Neurocrine Biosciences Inc trades as NBIX on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is NBIX in a Closelook index?

Not currently — Neurocrine Biosciences Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does NBIX trade against its moving averages?

Pullback inside an uptrend stack: Trades -6.8% vs the 50-day and +2.6% vs the 200-day average, 18.4% below the 52-week high and +24.3% off the 52-week low; a golden cross printed 75 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Neurocrine Biosciences Inc do?

Neurocrine Biosciences develops and sells medicines for neurological, psychiatric and endocrine conditions, working mainly across the United States. Its main marketed drug, INGREZZA, treats tardive dyskinesia and chorea linked to Huntington's disease, alongside Orilissa and Oriahnn for gynaecological conditions and CRENESSITY for a rare adrenal disorder. It also markets ALKINDI and Efmody and runs a pipeline of experimental compounds aimed at depression, schizophrenia, epilepsy, Alzheimer's disease and obesity, several developed under partnerships with firms such as Takeda, AbbVie, Sanofi, Xenon and Voyager. Closelook has not placed Neurocrine in a formal peer group; the market tends to set it beside other specialty neuroscience and psychiatric drug makers, such as Jazz Pharmaceuticals.

Where does Neurocrine Biosciences Inc sit in the AI build-out?

Neurocrine is not part of our AI build-out stack; it sits in the healthcare sleeve of our universe, within specialty drug manufacturing, as a developer and seller of neurological and endocrine therapies rather than a supplier to the compute or chip industries. Neurocrine holds a Russell 1000 seat within our coverage but carries no Closelook score yet, no Rubin or Halo membership, and no quotes or edition mentions in the diary so far.

What has Wall Street done on Neurocrine Biosciences Inc recently?

The most recent analyst action on Neurocrine Biosciences Inc on the Closelook wire is a price target by Morgan Stanley on 2026-09-11 (target 183 from 182). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for NBIX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.